Xencor, Inc Increase (Decrease) in Accounts and Other Receivables
Xencor, Inc (XNCR) reported Increase (Decrease) in Accounts and Other Receivables of -$21.51 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables · last filed 2022-11-07
- Xencor, Inc increase (decrease) in accounts and other receivables for the quarter ending 2022-09-30 was -$9.41M, a 280.23% decline year-over-year.
- Xencor, Inc increase (decrease) in accounts and other receivables for the quarter ending 2022-06-30 was -$38.92M.
- Xencor, Inc increase (decrease) in accounts and other receivables for the quarter ending 2022-03-31 was $26.82M, a 2378.74% increase year-over-year.
- Xencor, Inc increase (decrease) in accounts and other receivables for the quarter ending 2021-12-31 was $58.34M, a 2956.00% increase year-over-year.
- Xencor, Inc increase (decrease) in accounts and other receivables for fiscal 2021 was $54.94M.
- Xencor, Inc increase (decrease) in accounts and other receivables for fiscal 2020 was -$10.13M, a 189.49% decline from fiscal 2019.
- Xencor, Inc increase (decrease) in accounts and other receivables for fiscal 2019 was $11.32M, a 25.16% increase from fiscal 2018.
- Xencor, Inc increase (decrease) in accounts and other receivables for fiscal 2018 was $9.04M.
| Period end | Increase (Decrease) in Accounts and Other Receivables 3 month | Increase (Decrease) in Accounts and Other Receivables 6 month | Increase (Decrease) in Accounts and Other Receivables 6 month as first filed | Increase (Decrease) in Accounts and Other Receivables 9 month | Increase (Decrease) in Accounts and Other Receivables 9 month as first filed | Increase (Decrease) in Accounts and Other Receivables 12 month |
|---|---|---|---|---|---|---|
| 2022-09-30 | -$9.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$48.33M derived: sum of 2 quarters · filed 2022-11-07 | -$21.51M 10-Q · filed 2022-11-07 | $36.83M derived: sum of 4 quarters · filed 2022-11-07 | ||
| 2022-06-30 | -$38.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$12.10M 10-Q · filed 2022-08-03 | $46.24M derived: sum of 3 quarters · filed 2022-08-03 | $51.46M derived: sum of 4 quarters · filed 2022-11-07 | ||
| 2022-03-31 | $26.82M 10-Q · filed 2022-05-05 | $85.16M derived: sum of 2 quarters · filed 2022-05-05 | $90.38M derived: sum of 3 quarters · filed 2022-11-07 | $80.68M derived: sum of 4 quarters · filed 2022-11-07 | ||
| 2021-12-31 | $58.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $63.56M derived: sum of 2 quarters · filed 2022-11-07 | $53.86M derived: sum of 3 quarters · filed 2022-11-07 | $54.94M 10-K · filed 2022-02-24 | ||
| 2021-09-30 | $5.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$4.48M derived: sum of 2 quarters · filed 2022-11-07 | -$3.40M 10-Q · filed 2022-11-07 | $9.10M 10-Q · filed 2021-11-08 | -$1.49M derived: sum of 4 quarters · filed 2022-11-07 | |
| 2021-06-30 | -$9.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$8.62M 10-Q · filed 2022-08-03 | $3.38M 10-Q · filed 2021-08-04 | -$6.71M derived: sum of 3 quarters · filed 2022-08-03 | -$6.10M derived: sum of 4 quarters · filed 2022-08-03 | |
| 2021-03-31 | $1.08M 10-Q · filed 2022-05-05 | $2.99M derived: sum of 2 quarters · filed 2022-05-05 | $3.60M derived: sum of 3 quarters · filed 2022-05-05 | $5.70M derived: sum of 4 quarters · filed 2022-05-05 | ||
| 2020-12-31 | $1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $2.52M derived: sum of 2 quarters · filed 2022-02-24 | $4.62M derived: sum of 3 quarters · filed 2022-02-24 | -$10.13M 10-K · filed 2022-02-24 | ||
| 2020-09-30 | $609.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $2.71M derived: sum of 2 quarters · filed 2021-11-08 | -$12.04M 10-Q · filed 2021-11-08 | $5.18M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-06-30 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$12.65M 10-Q · filed 2021-08-04 | $4.58M derived: sum of 3 quarters · filed 2022-02-24 | -$1.21M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-03-31 | -$14.75M 10-Q · filed 2021-05-05 | $2.48M derived: sum of 2 quarters · filed 2022-02-24 | -$3.31M derived: sum of 3 quarters · filed 2022-02-24 | -$130.92M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2019-12-31 | $17.22M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $11.44M derived: sum of 2 quarters · filed 2022-02-24 | -$116.17M derived: sum of 3 quarters · filed 2022-02-24 | $11.32M 10-K · filed 2022-02-24 | ||
| 2019-09-30 | -$5.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$133.39M derived: sum of 2 quarters · filed 2020-11-06 | -$5.90M 10-Q · filed 2020-11-06 | $1.82M derived: sum of 4 quarters · filed 2021-02-24 | ||
| 2019-06-30 | -$127.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$122.00K 10-Q · filed 2020-08-05 | $7.60M derived: sum of 3 quarters · filed 2021-02-24 | $8.78M derived: sum of 4 quarters · filed 2021-02-24 | ||
| 2019-03-31 | $127.49M 10-Q · filed 2020-05-08 | $135.21M derived: sum of 2 quarters · filed 2021-02-24 | $136.39M derived: sum of 3 quarters · filed 2021-02-24 | $136.58M derived: sum of 4 quarters · filed 2021-02-24 | ||
| 2018-12-31 | $7.72M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $8.90M derived: sum of 2 quarters · filed 2021-02-24 | $9.09M derived: sum of 3 quarters · filed 2021-02-24 | $9.04M 10-K · filed 2021-02-24 | ||
| 2018-09-30 | $1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $1.36M derived: sum of 2 quarters · filed 2019-11-05 | $1.32M 10-Q · filed 2019-11-05 | $1.63M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-06-30 | $184.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $140.00K 10-Q · filed 2019-08-07 | $451.00K derived: sum of 3 quarters · filed 2020-02-25 | -$13.59M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-03-31 | -$44.00K 10-Q · filed 2019-05-09 | $267.00K derived: sum of 2 quarters · filed 2020-02-25 | -$13.78M derived: sum of 3 quarters · filed 2020-02-25 | -$5.84M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2017-12-31 | $311.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | -$13.73M derived: sum of 2 quarters · filed 2020-02-25 | -$5.80M derived: sum of 3 quarters · filed 2020-02-25 | -$7.47M 10-K · filed 2020-02-25 | ||
| 2017-09-30 | -$14.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | -$6.11M derived: sum of 2 quarters · filed 2018-11-05 | -$7.79M 10-Q · filed 2018-11-05 | -$2.26M derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2017-06-30 | $7.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $6.26M 10-Q · filed 2018-08-07 | $11.79M derived: sum of 3 quarters · filed 2019-02-26 | -$135.48M derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2017-03-31 | -$1.68M 10-Q · filed 2018-05-07 | $3.85M derived: sum of 2 quarters · filed 2019-02-26 | -$143.42M derived: sum of 3 quarters · filed 2019-02-26 | $6.29M derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2016-12-31 | $5.53M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$141.74M derived: sum of 2 quarters · filed 2019-02-26 | $7.97M derived: sum of 3 quarters · filed 2019-02-26 | $8.57M 10-K · filed 2019-02-26 | ||
| 2016-09-30 | -$147.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $2.44M derived: sum of 2 quarters · filed 2017-11-08 | $3.04M 10-Q · filed 2017-11-08 | |||
| 2016-06-30 | $149.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $150.31M 10-Q · filed 2017-08-07 | ||||
| 2016-03-31 | $604.00K 10-Q · filed 2017-05-10 | |||||
| 2015-12-31 | -$2.92M 10-K · filed 2018-02-28 | |||||
| 2014-12-31 | $2.91M 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |